Welcome to our dedicated page for Establishment Labs Hldgs SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Establishment Labs’ march toward global regulatory approvals means digging through dense SEC documents and clinical data tables. Whether you want the latest cost breakdown of Motiva IDE trials or need to see when executives buy shares after a new CE-mark, our platform turns hours of research into minutes.
Start with the filings most investors ask for: the Establishment Labs quarterly earnings report 10-Q filing for production cost trends, the Establishment Labs annual report 10-K simplified for R&D pipeline details, and every Establishment Labs 8-K material events explained to track FDA milestones. Each document arrives in real time directly from EDGAR, then Stock Titan’s AI distills the medical device jargon so you can focus on numbers that move the model.
Need insider context? Our alerts surface Establishment Labs insider trading Form 4 transactions and display Establishment Labs Form 4 insider transactions real-time, highlighting option exercises or open-market buys that often precede material announcements. Governance questions are answered in the Establishment Labs proxy statement executive compensation, where AI flags pay structures tied to regulatory achievements.
- Compare manufacturing expansion costs across quarters with instant charts from the 10-Q.
- Monitor Establishment Labs executive stock transactions Form 4 for sentiment shifts.
- Use our narrative summaries for Establishment Labs earnings report filing analysis when modeling margins.
- Save time understanding Establishment Labs SEC documents with AI—no medical dictionary required.
From biocompatibility disclosures to litigation updates, Stock Titan provides Establishment Labs SEC filings explained simply, so analysts, clinicians, and long-term investors can act with confidence.
Lewin Nicholas Sheridan, identified as a director of Establishment Labs Holdings, filed a Form 4 dated 08/14/2025 reporting insider transactions in the company’s common stock. The filing shows a purchase of 2,600 common shares at $37.85 and separately lists a disposition of 1,075,923 common shares. Following the reported transactions, the Form 4 shows 19,090 shares beneficially owned, held indirectly. A footnote states the shares are held by the reporting person’s spouse. The Form was signed by the company’s CFO by power of attorney on 08/14/2025.
Capital Research Global Investors reports beneficial ownership of 1,024,417 shares of Establishment Labs Holdings Inc., equal to 3.5% of 28,917,254 shares outstanding. The filing states that CRGI is a division of Capital Research and Management Company and related investment management entities that provide services under the name "Capital Research Global Investors." CRGI reports sole voting power and sole dispositive power over the 1,024,417 shares.
The filing further certifies the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing is categorized as an investment adviser (Type: IA).
Lewin N. Sheridan, a director of Establishment Labs Holdings Inc. (ESTA), reported transactions dated 08/13/2025. The Form 4 discloses a disposition of 1,075,923 common shares and an acquisition of 2,300 common shares at a price of $34.2955 per share. Following the reported transactions the filing shows 16,490 common shares beneficially owned indirectly. A footnote states the shares are held by the reporting person’s spouse. The form was submitted by a single reporting person and executed under power of attorney.
Filippo Caldini, who is listed as Chief Executive Officer and a director of Establishment Labs Holdings Inc. (ESTA), reported a purchase of common shares on 08/11/2025. The amended Form 4/A shows a purchase of 2,850 common shares at $35.20 per share, resulting in reported beneficial ownership of 35,245 shares. The transaction is reported with code P and the ownership is listed as direct (D).
The filing is an amendment (Form 4/A) submitted by a single reporting person and was signed on behalf of the reporting person by Rajbir S. Denhoy, Chief Financial Officer, by power of attorney. The document does not state total outstanding shares or the percentage that 35,245 shares represent, so the filing alone does not establish the transaction's materiality to shareholders.
Establishment Labs Holdings insider Filippo Caldini, who serves as both Chief Executive Officer and a director, reported purchases of 2,850 common shares of the company on 08/11/2025. The Form 4 shows a weighted average purchase price of $35.2 and reports total direct beneficial ownership after the transaction of 35,245 shares. The filing states the trades were executed in multiple transactions at prices ranging from $34.00 to $35.00 and that the reporting person will provide a full breakdown of shares purchased at each price upon request. No derivative securities were reported.
FAQ
What is the current stock price of Establishment Labs Hldgs (ESTA)?
What is the market cap of Establishment Labs Hldgs (ESTA)?
